The advent of obesity-indicated drugs like Wegovy, Saxenda, and Zepbound that have demonstrated not just weight loss, but also cardiovascular benefits has led insurance companies and policymakers alike to reconsider this class of drugs for formulary inclusion
For 503B outsourcing facilities, no equivalent safe harbor appears to apply, and enforcement grace periods that had been in place through early 2026 are expiring, leaving bulk compounders of GLP-1s in a substantially more precarious legal position
subtilis , Hansenula anomala , and L
LongSFXuYTPanLWangQQWangCLWuJYet al
Similar to a previous clinical study [18], these peptides significantly reduced lean mass, indicating that these GLP-1 analog peptides suppressed both fat and lean mass (Fig